Skip to main content

Rapid carbapenemase detection in enterobacterales using a lateral flow immunoassay: diagnostic performance and association with antimicrobial treatment decisions

In brief

Lateral-flow carbapenemase test matched PCR; 55% of positive cases had same-day escalation

In 205 Enterobacterales isolates, the lateral-flow test agreed with PCR on carbapenemase detection, with 100% positive and negative agreement; it correctly identified carbapenemase type in 95.5% of PCR-positive isolates overall. In the prospective group, same-day treatment escalation was more common with positive than negative results, but the observational association does not show the test caused clinicians to change therapy.

Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Q1)
Published
11 November 2026
Study design
Prospective / inception cohort
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Leyla Genç, İrem Zafer Üs, Şevval Arduç Tok, Özlem Gül, Hanife Tutan, Elif Seren Tanrıverdi, et al.
PMID
43013229
DOI
10.1007/s10096-026-05717-9

Why clinicians should know about it

  • Picked for Microbiology (medical) (top studies of the week, 15 November 2026): Direct comparison of rapid carbapenemase tests with molecular reference

Abstract

PURPOSE: Data on the association between same-day reporting of carbapenemase testing results using lateral flow immunochromatographic assays (LFA) and antimicrobial treatment decisions remain limited. This study aimed to evaluate the agreement between an LFA and commercial qPCR for carbapenemase detection and to compare the LFA with the Carba NP-direct test (CNPtd) and modified carbapenem inactivation method (mCIM). We also assessed the association between LFA results and same-day antimicrobial treatment decisions. METHODS: The study included 110 retrospective (80 carbapenemase-producing and 30 non-carbapenemase-producing) and 95 prospective Enterobacterales isolates. Agreement between the Carbapenem Resistant Enterobacteriaceae Test-Kit (Dynamiker Biotechnology, Tianjin, China), CNPtd, mCIM, and the Biospeedy Carbapenem Resistance qPCR Kit (Bioeksen, Türkiye) was evaluated using positive percent agreement (PPA) and negative percent agreement (NPA). The association between LFA positivity and treatment escalation was evaluated using multivariable logistic regression. RESULTS: In the retrospective cohort, the LFA showed 100% PPA and NPA with qPCR for carbapenemase detection, whereas CNPtd and mCIM showed PPA values of 85.0% and 80.0%, respectively, with 100% NPA for both methods. In the prospective cohort, the LFA also showed 100% PPA and NPA, whereas CNPtd and mCIM showed PPA values of 74.2% and 87.1%, respectively, with 100% NPA for both methods. Complete agreement between LFA and qPCR for carbapenemase type identification was observed in 106 of 111 qPCR-positive isolates (95.5%); five discrepancies involved isolates initially identified as carrying two carbapenemase genes by qPCR. In the prospective series, 31 of 95 isolates were carbapenemase-positive by qPCR, and the LFA showed complete agreement with PCR for carbapenemase detection and type identification (31/31). Same-day treatment escalation occurred in 55.2% (16/29) of those with LFA-positive isolates, compared with 9.7% (6/62) of those with LFA-negative isolates. LFA positivity was independently associated with treatment escalation (aOR, 7.94; 95% CI, 2.44-25.83; p = 0.001). CONCLUSION: The LFA demonstrated high agreement with qPCR for both carbapenemase detection and type identification. In the prospective series, LFA positivity was associated with same-day antimicrobial treatment escalation.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.